Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China to Test Embryonic Stem Cell Treatment for Parkinson's

publication date: Jun 2, 2017
The first China clinical trial using human embryonic stem (ES) cells will soon get underway. Zhengzhou University researchers in Henan Province plan to implant four million neuronal-precursor cells, developed from embryonic stem cells, into the brains of patients with Parkinson's disease. The goal will be to address the dopamine deficit that causes Parkinson's. The test will be the first China clinical trial of ES cells since 2015, when China adopted new rules to regulate stem cell experimentation and outlaw unproven stem cell treatments. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital